ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 551

Predictors Associated with Rheumatologist Referral Time in Patients with Ankylosing Spondylitis

Atul A. Deodhar1, Manish Mittal2, Patrick Reilly2, Yanjun Bao2, Shivaji Manthena2, Jaclyn K. Anderson2 and Avani D. Joshi2, 1Oregon Health and Sciences University, Portland, OR, 2AbbVie Inc., North Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Average delay between symptom onset and diagnosis of ankylosing spondylitis (AS) has been reported as 8–12.8 years1,2. This study assessed delay in AS diagnosis following diagnosis of back pain (BP), and sought to identify factors affecting time from BP diagnosis to rheumatologist referral in AS patients (pts).

Methods: This longitudinal study used claims data from the large US MarketScan® commercial insurance claims databases (total number of pts n = 127,137,195 between Jan 2000–Dec 2012). Pts aged 18–64 years with diagnosis of BP in a non-rheumatology setting followed by AS diagnosis in any setting were selected. Pts with a rheumatologist visit on/before AS diagnosis were considered to have been referred. A time-dependent Cox proportional hazard model was used to determine factors associated with referral time after adjusting for age, sex, comorbidities, physician specialty, drug therapy and imaging procedures.

Results: Out of 3,336 pts diagnosed with AS after a diagnosis of BP, 1,244 (37%) were referred to and diagnosed by rheumatologists; remaining were diagnosed in a primary care (PCP; 25.7%), chiropractor/physical therapy (7%), orthopedic (3.8%), pain (3.6%), acute care (3.4%) or other (19.2%) setting. More referred pts were prescribed NSAIDs, DMARDs, corticosteroids and anti-TNF prior to diagnosis of AS, suggesting potentially more severe AS (Table 1). In the time between the diagnoses of BP and AS, 75 (6%) of referred patients were prescribed anti-TNF therapy by rheumatologists and 42 (2%) of non-referred patients were prescribed anti-TNFs by PCPs. Referred pts were also more likely to have had spinal/pelvic imaging procedures (x-ray, MRI, CT scan). Median time from BP diagnosis to rheumatologist referral was 307 days and median time from first rheumatologist visit to AS diagnosis was 28 days. Referred pts were more likely to be younger, male, diagnosed with uveitis, referred by PCPs, prescribed NSAIDs, DMARDs, and anti-TNF prior to referral, and to have had spinal/pelvic x-ray (Table 2).

Conclusion: During 2000–2012, the majority of AS patients who presented with BP were diagnosed without rheumatologist referral. Among those referred, there was a delay of approximately 10 months before a rheumatologist referral was made. After a rheumatologist visit, diagnosis of AS generally followed within a month. Predictors of referral time included young age, male sex, presence of uveitis, use of drug therapy and imaging procedures, and referring physician specialty.

References:

1.      Collantes E et al. Rheumatology 2007;46:1309-15.

2.      Kiltz U et al. Ann Rheum Dis. 2012;71:1207-11.

 

Table 1. Patient Characteristics

Characteristic

Patients referred to rheumatologist (n=1,244)

Patients not referred to rheumatologist (n=2,092)

Age, years

42.9

45.8

Female, %

50.7%

50.0%

Comorbid condition, %

Diabetes

5.1%

9.8%

Cardiovascular disease

7.1%

10.2%

Hypertension

18.4%

23.5%

Renal disease

0.5%

1.1%

Cancer

17.3%

19.0%

Uveitis

4.3%

3.9%

Prescribed Drug Therapy, %

NSAID

64.8%

53.9%

DMARD

28.0%

13.9%

Corticosteroid

58.3%

41.5%

Opiate

57.5%

56.3%

Anti-TNF

10.2%

3.4%

Spinal/Pelvic Imaging Procedure, %

x-ray

71.3%

56.4%

MRI

42.3%

38.7%

CT scan

18.4%

17.0%

DMARDs=disease-modifying antirheumatic drug; MRI=magnetic resonance imaging; NSAIDS=non-steroidal antiinflammatory drug; TNF=tumor necrosis factor.

 

Table 2. Factors Associated with Rheumatologist Referral Time for Patients with Ankylosing Spondylitis in multivariate analysis

Predictor

HR (95% CI)

Age

0.986 (0.981, 0.991)

Sex (M vs F)

1.15 (1.03, 1.29)

Uveitis

1.49 (1.13, 1.96)

Specialty

PCP

1.96 (1.64, 2.35)

Pain management

0.79 (0.69, 0.91)

Prescribed Drug Therapy

NSAID

1.55 (1.35, 1.77)

DMARD

1.33 (1.16, 1.54)

Opiate

0.82 (0.72, 0.94)

Anti-TNF

1.40 (1.12, 1.76)

Spinal/Pelvic Imaging Procedure

x-ray

1.28 (1.12, 1.46)

CT scan

0.71 (0.58, 0.87)

CI=confidence interval; DMARDs=disease-modifying antirheumatic drug; HR=hazard ratio; MRI=magnetic resonance imaging; NSAIDS=non-steroidal antiinflammatory drug; PCP=primary care physician; TNF=tumor necrosis factor.

 


Disclosure:

A. A. Deodhar,

Abbvie, Celgene, Novartis, Pfizer, UCB, Janssen,

2,

Abbvie, Celgene, Novartis, Pfizer and UCB,

9,

Abbvie, Celgene, Novartis, Pfizer and UCB,

9;

M. Mittal,

AbbVie,

1,

AbbVie,

3;

P. Reilly,

AbbVie,

1,

AbbVie,

3;

Y. Bao,

AbbVie,

1,

AbbVie,

3;

S. Manthena,

AbbVie,

1,

AbbVie,

3;

J. K. Anderson,

AbbVie,

1,

AbbVie,

3;

A. D. Joshi,

AbbVie,

1,

AbbVie,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-associated-with-rheumatologist-referral-time-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology